🔎 What This Document Is

This is a Post-Effective Amendment to a registration statement. Think of it as an updated and finalized sales brochure for a fundraising round. XORTX Therapeutics has already filed to sell stock, and this document is the final, official version of the offering details filed with the SEC on April 23, 2026. It outlines a plan to sell new shares to the public to raise cash.

👉 Why it matters: This isn't about the company's latest earnings. It's a formal "We are selling more stock, and here are the exact details" announcement for potential investors.

🧬 What The Company Does

In simple terms, XORTX Therapeutics is a clinical-stage biotechnology company. They are in the business of developing medicines, specifically targeting kidney diseases like Autosomal Dominant Polycystic Kidney Disease (ADPKD). They don't have a product on the market yet; their value is tied to their research pipeline and potential future drugs.

👉 Why it matters: This is a high-risk, high-reward profile common to biotech. Their future depends on clinical trial successes, not current sales. They are listed on both the Nasdaq (under XRTX) and the TSXV in Canada.

💰 The Fundraising: What's Being Offered

XORTX is conducting a "reasonable best efforts" offering. This means their agent, E.F. Hutton & Co., will try hard to sell the shares but doesn't guarantee a specific amount will be raised.

• What's for sale: Up to 2,202,643 common shares OR Pre-Funded Warrants to buy the same number of shares.
• Assumed Price: The example price used is $2.27 per share, which was the stock's closing price on April 17, 2026.
• The Pre-Funded Warrant Twist: For very large investors who don't want to exceed ownership thresholds (like 4.99% or 9.99% of the company), they can buy these special warrants instead. They cost $2.2699 (basically $2.27 minus $0.0001) and can be "exercised" into a share anytime for just a penny more.

👉 Why it matters: The Pre-Funded Warrants are a financial engineering tool. They let big money participate without immediately triggering regulatory ownership disclosures, making the offering more attractive to certain institutional investors.

💵 Use of Proceeds: Where the Money Goes

The company hasn't locked down exactly how every dollar will be spent. However, they state the proceeds will fund their general business objectives. A key planned expenditure is up to $2 million for investor relations and marketing services to raise their profile. The bulk is expected for working capital—the cash needed to run day-to-day operations while they develop their drugs.

👉 Why it matters: This is a "fuel for the runway" offering. For a pre-revenue biotech, cash is everything. This money funds operations and clinical trials until they can potentially launch a product. Management has broad discretion on the final spending.

⚠️ Financial Health & Risks

The filing is clear about the company's current state:

• Operating Losses: They incurred losses for the fiscal years 2024 and 2025.
• Cash Burn: They had negative operating cash flow in those same years.
• Dilution: This offering will create more shares, meaning each existing share represents a smaller slice of the company (dilution).
• No Dividends: The company has never paid a dividend and doesn't plan to.

👉 Why it matters: This is standard for a development-stage biotech, but it highlights the core risk: the company is burning cash and relies entirely on investor funding and future success to survive.

📜 Key Tax Considerations for Investors

A large portion of this filing explains the complex tax implications, especially since XORTX is a Canadian company.

• For Canadian Investors: Rules are covered for capital gains, dividends, and holding shares in registered plans like RRSPs or TFSAs.
• For U.S. Investors: The company warns it is likely a Passive Foreign Investment Company (PFIC). This is a special, often disadvantageous, tax classification for U.S. shareholders that can lead to higher taxes and complex reporting. The filing details the complicated rules and elections (like QEF or Mark-to-Market) available to mitigate this.

👉 Why it matters: The PFIC status is a major red flag for U.S. investors. It adds significant tax complexity and potential cost, which could make the stock less attractive. All investors must read the tax section carefully.

🧠 The Analogy

Investing in XORTX right now is like funding a team of brilliant scientists who have a promising blueprint for a revolutionary water filter (a drug for kidney disease). They have no finished filter to sell yet. They're holding a bake sale (this stock offering) to buy lab equipment and materials to build and test their prototype. If the prototype works, everyone who bought a cupcake (a share) could make a lot of money. But there's a real chance the experiment fails, and the cupcake money is gone. Plus, the tax rules for this bake sale are notoriously complicated.

🧩 Final Takeaway

XORTX Therapeutics is raising cash through a share offering to fund its ongoing research into kidney disease treatments. As a pre-revenue biotech, this is a high-risk investment dependent on future clinical success, complicated further by the company's PFIC tax status for U.S. investors and significant shareholder dilution from the offering. This money is crucial for survival but doesn't guarantee success.